ReviewGut and liver2017
Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics.
Review in Gut and liver, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 2 syntheses or guidelines pooled it, 149 citations in OpenAlex.
- Efficacy and safety of IL-23 p19 inhibitors in the treatment for inflammatory bowel disease: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysis.United European gastroenterology journal · 2023Pooled it
- Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption.Frontiers in endocrinology · 2021Trial
- Phytotherapeutic potential of Gossypium barbadense L. root as an alternative therapy for colitis: a comprehensive review with network pharmacology insights.Inflammopharmacology · 2026Review
- Article
- Granzyme B PET Imaging Uncovers Dynamic Patterns of Disease Activity and Therapeutic Response in a Murine Colitis Model.International journal of molecular sciences · 2026Article
- Modulation of Inflammatory and Apoptotic Pathways by Tamarix Aphylla Essential Oil in TNBS-Induced Colitis: A Focus on Cytokine Balancing, NF-κB, p38 MAPK, and Nrf2 Activation.Applied biochemistry and biotechnology · 2026Article
- Synthetic mucus biomaterials enable localized therapeutic antibody delivery in inflammatory bowel disease.APL bioengineering · 2026Article
- Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs) and Small Intestinal Submucosa (SIS) Hydrogel Composite Can Meliorate TNBS-Induced Experimental Colitis Through Regulating Inhibiting Macrophage Polarization Toward the M1 Phenotype.Mediators of inflammation · 2026Article
- Future of inflammatory bowel disease treatment: A review of novel treatments beyond guidelines.World journal of methodology · 2025Review
- Review
- Oxidative Stress-Related Biomarkers in Inflammatory Bowel Disease: Dual Tools for Remission Assessment and Prediction of Treatment Outcome.Antioxidants (Basel, Switzerland) · 2025Article
- Focal adhesion kinase: A promising regulator of colitis-associated healing.World journal of gastroenterology · 2025Review
- Vibrational exercise for Crohn's to observe response (VECTOR): Protocol for a randomized controlled trial.PloS one · 2025Article
- Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World Data.Canadian journal of gastroenterology & hepatology · 2025Article
- Mechanism of cell death and its application in the repair of inflammatory bowel disease by mesenchymal stem cells.Frontiers in immunology · 2025Review
- Zhumeria majdae essential oil attenuates TNBS-induced colitis in rats by regulating inflammatory and apoptotic pathways.Inflammopharmacology · 2024Article
- Inflammation-targeted delivery of Urolithin A mitigates chemical- and immune checkpoint inhibitor-induced colitis.Journal of nanobiotechnology · 2024Article
- Curcumin-Encapsulated Co-ZIF-8 for Ulcerative Colitis Therapy: ROS Scavenging and Macrophage Modulation Effects.ACS omega · 2024Article
- Sirtuin 3 ameliorates inflammatory bowel disease via inhibiting intestinal inflammation and oxidative stress.Journal of clinical biochemistry and nutrition · 2024Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable progress in IBD therapy. Some patients, however, do not respond to anti-TNF treatment, or their response decreases over time. This phenomenon highlights the need to identify new molecular targets for therapy in IBD. The targets of new therapeutic molecules in IBD must aim to restore immune dysregulation by the inhibition of proinflammatory cytokines (TNF-α, interleukin [IL]-6, IL-13, IL-17, IL-18, and IL-21) and augmentation of the effect of anti-inflammatory cytokines (IL-10, IL-11, and transforming growth factor β) and to pursue new anti-inflammatory targets, such as regulatory T-cell therapy, Smad7 antisense, Janus-activated kinase inhibition, Toll-like receptor stimulation, leukocyte adhesion, and blockade of T-cell homing via integrins and mucosal addressin cellular adhesion molecule-1. In addition, potential molecular targets could restore mucosal barrier function and stimulate mucosal healing. Despite these potential targets, the value and clinical significance of most new molecules remain unclear, and clinical efficacy and safety must be better defined before their implementation in clinical practice. This article aims to review the promising and emerging molecular targets that could be clinically meaningful for novel therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.